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ABSTRACT
Neurotensin (NTS), localized predominantly to the small bowel, stimulates the 
growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly 
through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we 
observed increased expression of NTSR1 in almost all tested clinical NET samples, 
but not in normal tissues. Through RT-PCR analysis, we found that the expression 
of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET 
cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment 
with 5-aza-2′-deoxycytidine, a demethylating agent, increased levels of NTSR1 and 
NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, 
which was confirmed by methylation analyses. In addition, we found that knockdown 
of NTSR1 decreased proliferation, expression levels of growth-related proteins, and 
anchorage-independent growth of BON human carcinoid cells. Moreover, stable 
silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our 
results show that high expression of NTSR1 is found in clinical NETs and that promoter 
methylation is an important mechanism controlling the differential expression of 
NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in 
BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET 
tumorigenesis.
INTRODUCTION
Neurotensin (NTS), a 13-amino acid peptide, 
functions as a primary neurotransmitter as well as a 
neuromodulator in the central nervous system (CNS) and 
as a hormone in the periphery [1–3]. NTS contributes to 
numerous physiologic functions in the gastrointestinal 
(GI) tract including GI secretion, gut motility, and 
growth of various normal tissues [1, 2]. Moreover, NTS 
stimulates the growth of several cancer types including 
neuroendocrine tumors (NETs) that, compared to other 
cancers, are increasing in incidence [1, 3, 4].
The actions of NTS are mediated through three 
receptors (i.e., NTSR1, NTSR2 and NTSR3/sortilin), 
named according to the order in which they were 
cloned [2, 3]. In particular, high-affinity NTSR1, which is 
found in various regions of the CNS, in the small and large 
intestine, and in a variety of solid tumors, is considered 
a predominant mediator of the effects of NTS on cell 
proliferation, migration, and invasion [3, 5]. In contrast, 
the  low-affinity  NTSR2,  which  shares  60%  homology 
with NTSR1, demonstrates a more localized distribution; 
the expression of NTSR2 has been recently reported in 
prostate cancers and B cell lymphomas [6, 7]. Different 
from NTSR1 and NTSR2, which are G protein-coupled 
receptors, NTSR3/sortilin is a single transmembrane 





of genes that are important for cancer development and 
progression [9–11]. For example, it is well known that 
hypermethylation of CpG islands in the promoter region 
of tumor suppressor genes results in gene silencing, which 
can lead to the facilitation of tumor progression in certain 
tissues [9, 12]. In addition, DNA hypomethylation, which 
is also observed in many cancers, induces transcriptional 
activation of oncogenes and contributes to cancer 
progression [9, 13, 14].
Diverse expression levels of the NTSRs, especially 
increased expression of NTSR1, have been reported in 
various types of cancers (e.g., colon, pancreas, breast, 
lung and prostate) [15–21]; however, the molecular 
mechanisms for this altered expression pattern are not 
entirely known. Although NTS can stimulate the growth 
of  NET  cells  [4],  the  expression  profiles  and  cellular 
functions of the NTSRs have not been well-delineated in 
NETs. In our present study, we analyzed the expression 
of NTSR1 protein in normal and NET tissues for GI, 
lung and thymus, and endogenous expression of NTSRs 
and transcriptional repression of NTSR1 and NTSR2 
genes in NET cell lines. We demonstrate the epigenetic 
alteration of NTSR1 and NTSR2 by methylation analyses 
of their promoters in NET cells and in clinical tissues. 
Furthermore, we show that NTSR1 knockdown suppresses 
cell proliferation, anchorage-independent growth, 
attachment, migration and invasion of NET cells.
RESULTS
Expression of NTSR1 in normal and NET tissues 
by immunohistochemistry
NTS and NTSR1 complexes have been frequently 
observed in progression of several types of tumors. 
Although  the  expression  of  NTS  which  is  mainly 
released by endocrine cells in the small bowel is broadly 
known in NETs, NTSR1 expression has not been 
well-studied in NETs. To evaluate the expression of 
NTSR1, immunohistochemical analysis was performed 
in clinical NET patient samples (i.e., 12 GI, 2 thymus 
and 6 lung NET tissues) used in our previous study [22]. 
Compared to normal tissues (5 GI, 2 thymus and 5 lung 
tissues) in which NTSR1 was not or barely detected, 
increased expression of NTSR1 was observed in all tested 
GI (12 of 12 NETs, Fig. 1A), and thymus (2 out of 2 NETs, 
Figure 1: Expression of NTSR1 in normal and clinical NET tissues. Immunohistochemical analysis of NTSR1 was performed 
in human normal and NET tissues. Representative images for NTSR1 protein expression in GI A. thymus B. and lung C. were shown 
at 200 × magnification. While the staining of NTSR1 was absent or barely detected in normal tissues (left), strong NTSR1 labeling was 
observed in clinical NET tissues (right).
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Fig. 1B), and a majority of lung (5 out of 6 NETs, Fig. 1C) 
NET samples. These data suggest that NTSR1 is highly 
expressed in NETs but not in normal tissues.
Endogenous expression of NTS and NTSRs, and 
induction of NTSR1 and NTSR2 by 5-aza-CdR 
treatment in NET cells
To  elucidate  expression  profiles  of  NTS  signaling 
components in NET cells, we first analyzed the expression 




(data not shown). Variable expression of NTSR1 was noted 
with the greatest expression in NCI-H727 cells and moderate 
expression in BON; very little or no NTSR1 transcripts were 
demonstrated in QGP-1 and UMC-11 cells (Fig. 2A).
Previously, we found that repression of Wnt 
inhibitory genes (SFRP-1, Axin-2, DKK-1, DKK-3 and 
WIF-1) results from promoter methylation or histone 
modification  in NET  cells  [22].  To  determine whether 
alterations in expression levels of NTSR1 and NTSR2 
were due to epigenetic mechanisms (e.g., promoter 
methylation), we treated BON and QGP-1 cells with a 
demethylating agent, 5-aza-2’-deoxycytidine (5-aza-
CdR), and examined the expression of NTSRs using 
RT-PCR (Fig. 2B). Treatment with 5-aza-CdR increased 
the expression of NTSR1 and NTSR2 in BON and the 
expression of NTSR1 in QGP-1 cells. To confirm these 
results, mRNA expression levels were also investigated 
by qRT-PCR (Fig. 2C). Treatment of the cells with 5-aza-
CdR  resulted  in  an  approximate  57-fold  induction  of 
NTSR1 expression in BON and an approximate 5-fold 
induction in QGP-1 cells. Western blot analysis confirmed 
that the level of NTSR1 protein was augmented in BON 
cells treated with 5-aza-CdR (Fig. 2D). Collectively, our 
findings  of mRNA and protein  expression  suggest  that 
NTSR1 and NTSR2 are targets of epigenetic modulation 
through methylation in NET cells.
Figure 2: Expression analysis of NTSRs in endogenous and 5-aza-CdR treated NET cell lines. A. RT-PCR analysis of NTS, 
NTSR1, NTSR2, NTSR3 and β-actin expression in NET cells. B. RT-PCR analysis of NTSRs and β-actin expression in BON and QGP-1 
cells treated with 0 (DMSO) or 10 μM 5-aza-CdR. The media containing 5-aza-CdR were replaced every 24 h for 4 d. C. Quantitative 
RT-PCR (qRT-PCR) analysis confirmed that treatment with 5-aza-CdR increased the expression of NTSR1 gene in BON and QGP-1 cells. 
The reaction was performed using a TaqMan Gene Expression Master Mix and TaqMan probes for human NTSR1 and GAPDH as internal 
control (Applied Biosystems). Expression levels were assessed by evaluating threshold cycle (Ct) values. The relative amount of mRNA 
expression was calculated by the comparative ∆∆Ct method (*p < 0.05 vs. DMSO). D. Western blot analysis showing induction of NTSR1 
by 5-aza-CdR treatment for 96 h in BON cells. The protein extracts for cell lysates were analyzed with the indicated antibodies. β-actin 
was used as a loading control.
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Methylation status of NTSR1 and NTSR2 
promoters in NETs
To test whether the induction of NTSR1 and NTSR2 by 
5-aza-CdR was due to promoter methylation, we examined 
the methylation status of the 5’ regions of these genes using 
methylation-specific PCR (MSP) and bisulfite sequencing in 
three NET cell lines. Using two primer pairs, MSP analysis 
showed partial methylation of the NTSR1 promoter in all 
tested cell  lines  (Fig. 3A). The methylation profile of  the 
5’ region of NTSR1 was further analyzed by the direct 
sequencing of the MSP products (Supplementary Fig. 1A) 
and bisulfite  sequencing  (Fig.  3B). The CpG  sites  of  the 
NTSR1 promoter were partially methylated in tested NET 
cells. Moreover, promoter methylation of NTSR2 was also 
noted by MSP analysis (Fig. 3A). Similar sequencing analyses 
for  the NTSR2  promoter  confirmed  hypermethylation  of 
the CpG islands consistent with the MSP data (Fig. 3C and 
Supplementary Fig. 1B).
CpG island methylation of NTSR1 and NTSR2 
was further investigated in the above clinical specimens 
used in immunohistochemical analyses. By MSP 
analysis, methylation of the NTSR1 promoter was not 
noted in any of the NET specimens, and methylation 




circles indicate methylated and unmethylated CpG sites, respectively. Bold grey lines are candidate CpG islands searched by the software 
of Applied Biosystems. The thicker and upper, and thinner and lower arrows below the CpG islands represent the primers for bisulfite 
sequencing and MSP, respectively. C. Bisulfite genomic sequencing analysis of NTSR2 CpG islands in the NET cells. D. MSP analysis of 
NTSR1 and NTSR2 promoters with the same primers described above in clinical NET samples.
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of NTSR2 was observed in 12 out of 19 NET samples 
(Fig. 3D). Surprisingly, promoter methylation of NTSR1 
was shown in 11 out of 12 normal tissues samples 
(Supplementary Fig. 2). These data demonstrate that 
reduction or silencing of NTSR gene expression was 
strongly associated with DNA methylation of the respective 
gene promoters in NET cell lines and patient samples. In 
particular, the absence of NTSR1 promoter methylation is 
in line with NTSR1 protein expression (Fig. 1) and leads 
to a strong expression of the protein in tested clinical 
NET  samples.  In  addition, Dong  et al.  [25,  26]  in  our 
laboratory reported that DNA methylation contributes to 
NTS expression in human liver and colon cancer cells. 
Therefore, based on our current study and previous 
reports, it is clear that DNA methylation can control NTS 
signaling by regulation of expression levels for the agonist 
(i.e., NTS) and its receptors (NTSR1 and NTSR2).
NTSR1 knockdown inhibits NET cell growth  
and migration
Recently, we showed that expression and secretion 
of  NTS  are  directly  regulated  by  the  Wnt/β-catenin 
pathway in NET cells [4]. We also found that inhibition 
of NTS signaling suppressed cell proliferation and 
anchorage-independent growth in these cells [4]. To 
further delineate the possible proliferative effect of 
NTSR1, we used small interfering RNA (siRNA) against 
NTSR1  in  BON  cells,  which  express  NTSR1  mRNA 
and have been widely utilized as a novel carcinoid cell 
model [27]. Compared with cells  transfected with non-
targeting control, siRNA-mediated knockdown of NTSR1 




agar assays to determine the effect of NTSR1 knockdown 




of NTS may be mediated mainly by NTSR1 in NET cells.
In addition to cell growth, activation of NTSR1 
induces cell migration, invasion, and metastasis in head 
and neck squamous cell carcinomas, glioblastomas and 
breast cancer cells [19, 30, 31]. Based on these studies, 
we evaluated the migration of BON cells transfected with 
NTSR1 siRNA using a Boyden chamber migration assay 
with type I collagen-coated Transwells. Knockdown of 
NTSR1 decreased the migratory potential of BON cells at 
Figure 4: Knockdown of NTSR1 affects NET cell growth and migration. A. Equal numbers of BON cells transfected with 
siRNA against non-targeting control or NTSR1 were plated in 24 well plates. The cell numbers were counted after 48 h incubation using 
a cell counter (*p < 0.05 vs. control siRNA). B. RT-PCR (left) and western blot (right) analyses showing expression of NTSR1, c-Myc 
and Cyclin D1 in BON cells transfected with control or NTSR1 siRNA. β-actin was used as a loading control. C. The number of colonies 
compared with the control siRNA in soft agar assay. Colony formation of representative control or NTSR1 knockdown BON cells was 






the effect of pharmacologic blockade of NTSR1 using 
SR-48692  on  NET  cell  migration  was  assessed  by 
Transwell migration assays. Treatment with SR-48692, 
which  represses  NET  cell  growth  [4],  significantly 
decreased BON cell migration in a dose-dependent 
manner (Supplementary Fig. 3A). Taken together, these 
findings show that knockdown of NTSR1 through siRNA 
or treatment with a selective NTSR1 antagonist inhibits 
cell growth and migration of NET cells.
Stable silencing of NTSR1 suppresses 
proliferation, adhesion, migration and  
invasion in NET cells
To further investigate the contribution of NTSR1 
on NET cell proliferation, adhesion, migration and 
invasion, we utilized NTSR1 small hairpin RNA (shRNA) 
to establish stable BON cell clones (N-2 and N-3) with 
low levels of NTSR1 expression following puromycin 
selection  (Fig.  5A).  The  stable  shRNA-mediated 





Consistent with results obtained from the above 
experiments using siRNA, the inhibition of cell growth 
and suppression of anchorage-independent growth was 
also  noted  in  the  cell  lines  expressing NTSR1  shRNA 
compared with control cells (Fig. 5B and 5C). In addition, 
an adhesion assay was performed to assess cell binding 
ability to the extracellular matrix which is crucial for 
maintaining cell viability and migration [33]. The stably-
silenced NTSR1 clones demonstrated lower numbers of 
attached cells on type I collagen-coated plates compared 
with control cells (Fig. 5D and Supplementary Fig. 3B). 
Furthermore, BON cell clones expressing shRNA targeting 
Figure 5: Stable silencing of NTSR1 suppresses cell growth, adhesion, migration and invasion of NET cells. A. RT-PCR 
(upper) and western blot (bottom) analyses showing NTSR1 expression in stable non-targeting control or two NTSR1 knockdown BON cell 
clones (N-2 and N-3). B. The stable BON cell clones were incubated for 48 h; cell numbers were counted using a cell counter (*p < 0.05 
vs. control shRNA). C. The number of colonies compared with control shRNA in soft agar assay. Colony formation of representative BON 
stable cell clones was assessed over a period of 4 wks (*p < 0.05 vs. control shRNA). D. The same number of stable BON cells was added 
onto type I collagen-coated plate for 15 min. The attached cells were fixed, and then stained with crystal violet. The number of attached cells 
was counted and the mean values were determined (*p < 0.05 vs. control shRNA). E. Phase-contrast microscopic images showing stable 
BON cell clones 2 h (upper) and 22 h (bottom) after removing the Culture-Insert (Ibidi, Munich, Germany). Wounding migration assay 
performed with control and the two BON cell clones expressing NTSR1 shRNA over 22 h. Quantification was carried out by measuring the 




NTSR1  showed  significantly  decreased  cell  migration 
compared to control cells (Fig. 5E). Finally, to examine the 
intravasation effect of NTSR1, the human Alu sequence 
PCR-based chick chorioallantoic membrane (CAM) assay 
was performed as described previously [34]. Compared to 
that of control, amplified bands of lower CAM inoculated 
with  NTSR1-transfected  BON  cells  were  significantly 
decreased indicating that the invasive capacity of BON 
cells was diminished in NTSR1 knockdown clones 
(Fig. 5F). Collectively, these findings confirm that stable 
silencing of NTSR1 markedly inhibits cell proliferation, 
anchorage-independent growth, cell adhesion, migration 
and invasion suggesting an oncogenic function for NTSR1 
in NET cells.
DISCUSSION
There is emerging evidence that either NTS or 
NTSR1 can be utilized as a prognostic marker for various 
cancers due to aberrant expression noted in tumors and 
not detected in normal tissues, and that silencing of the 
genes can inhibit the tumorigenic activities in some cancer 
cells [15–21]. In particular, NTSR1 expression is strongly 
associated with a worse survival and a higher incidence 
of distant metastases in lung and breast cancers [17, 20]. 
However, the mechanisms for the expression of NTSR1 in 
cancer tissues including NETs, have not been well-defined. 
Here, we showed that NTSR1 protein is not or barely 
detected in 12 normal tissues but is strongly expressed in 
95% of clinical NET samples (19 of 20 NETs). Similar to 
the above described cancers, high expression of NTSR1, 
noted in this study, and NTS are associated with NET 
progression indicating that NTSR1 may be a useful 
prognostic marker for NETs.
We also found that differential expression of 
NTSR1 and silencing of NTSR2 in NET cells is a result 
of promoter methylation. Previously, it was reported 
that  DNA  methylation  plays  an  important  role  in  the 
regulation of NTS expression in human cancer cells 
[25,  26].  Similar  to  the Wnt/β-catenin  pathway  which 
regulates the expression of both NTS and NTSR1 [4, 35], 
promoter methylation demonstrates a complicated 
regulatory process for NTS signaling at the level of the 
agonist as well as the simultaneous regulation of its 
receptors. In addition to hypermethylation, which is 
commonly found with tumor initiation and progression, 
hypomethylation of certain genes (e.g., urokinase 
plasminogen activator) is a common mechanism for the 
aberrant gene expression patterns in tumors, and plays 
a central role in human tumor progression [14, 36–38]. 
Similarly, the lack of NTSR1 promoter methylation is 
observed in all NET tissues and the promoter methylation 
was shown in most normal tissues in this study. These data 
represent that the absence of promoter methylation closely 
correlates with overexpression of NTSR1 in NET clinical 
samples. Histone modification could also be related to its 
transcriptional regulation similar to epigenetic repression 
of DKK-1, DKK-3 and WIF-1 noted in our previous study 
showing that silencing of these genes occurs through 
histone  modification  in  NET  cells,  although  the  Wnt 
inhibitors are silenced by methylation of their promoters in 
most tumors [22]. Further work is required to elucidate the 
detailed mechanisms for epigenetic silencing of NTSR1 
and NTSR2 in diverse tumor types.
NTS and NTSR1 are neuropeptide-receptor 
complexes which are frequently deregulated during tumor 
progression [3, 5]. In particular, NTSR1 activation induces 
cell proliferation, survival, migration and invasion through 
multiple oncogenic pathways in various cancers [3, 5]. 
Recently, we proposed that NTS is a mediator for NET 
cell growth through inhibition of NTS signaling [4]. In 
our current study, we confirmed the high expression of 
NTSR1 protein in clinical NET tissues as described above 
and analyzed the effect of NTSR1 on NET cell growth, 
adhesion, migration and invasion to better delineate the 
significance of NTSR1 in NET progression. In addition 
to cell proliferation and anchorage-independent growth, 
which were suppressed by NTS knockdown, NTSR1 
silencing resulted in reduction of NET cell migration and 
invasion indicating that NTSR1 is mainly engaged in NET 
progression.
In  summary,  we  have  identified  promoter 
methylation as an important molecular mechanism for 
the regulation of NTSR1 and NTSR2 expression. In 
addition, we also demonstrate high expression of NTSR1 
protein in clinical NETs, and the oncogenic function of 
NTSR1 in NET cells. Our findings identify a potential role 
for NTSR1 in the growth and progression of NETs and 
provide a rationale for further exploration of NTSR1 as a 
therapeutic target for NET treatment.
MATERIALS AND METHODS
Immunohistochemistry
Immunostaining with NTSR1 antibody, obtained 
from Abcam (ab117592, Cambridge, MA), was performed 
as  described  previously  [22].  The  slides  for  paraffin-
embedded tissue blocks of NETs from GI (n = 12), lung 
(n = 6) and thymus (n = 2) and normal tissues from GI 





Cell culture and treatment, siRNA transfections 
and lentiviral transductions
Four human NET cell lines, BON (pancreatic 
carcinoid), QGP-1, (pancreatic somatostatinoma), 
NCI-H727 (bronchial carcinoid) and UMC-11 (bronchial 
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5%  FBS.  QGP-1,  NCI-H727  and  UMC-11  cells  were 
cultured  in  RPMI1640  medium  with  10%  FBS.  Cells 
were grown at 37°C in a humidified 5% CO2 incubator. 
Reagents for cell treatment, a demethylating agent, 
5-aza-2’-deoxycytidine and an NTSR1 antagonist, 
SR-48692 were purchased from Sigma (St Louis, MO) 
and dissolved in dimethyl sulfoxide (DMSO). Transfection 
with  nontargeting  control  and  SMARTPool  NTSR1 
siRNA (Dharmacon, Lafayette, CO) was performed using 
Lipofectamine  RNAiMAX  (Invitrogen,  Carlsbad,  CA) 
as previously described [4]. For generation of NTSR1-
silenced BON cells, the shRNA lentiviruses were produced 
using  shRNA  vectors  (SHGLY-NM_002531,  Sigma). 
Cells were transduced with each virus and then selected 
with puromycin (2 μg/mL) as previously reported [4, 39].
RNA isolation, reverse transcription-PCR  
(RT-PCR) and quantitative reverse 
transcription-PCR (qRT-PCR) analysis
Total  RNA  was  isolated  from  the  cultured  NET 
cells using RNeasy kits according to the manufacturer’s 
instructions  (Qiagen,  Valencia,  CA).  Each  cDNA 
was  synthesized  using  High-Capacity  cDNA  Reverse 
Transcription  Kit  (Applied  Biosystems,  Foster  City, 
CA)  and  total  RNA  for  NET  cells.  RT-PCR  analysis 
was  performed  using  synthesized  cDNA,  HotStarTaq 
DNA  Polymerase  (Qiagen)  and  the  primers  described 
in Supplementary Table S1. The PCR products were 
analyzed on  a  2% agarose  gel.  β-actin was  used  as  an 
internal control. qRT-PCR reaction was performed using 
a TaqMan Gene Expression Master Mix and TaqMan 
probes for human NTSR1 and GAPDH according to the 
manufacturer’s protocol (Applied Biosystems). Expression 
levels were assessed by evaluating threshold cycle (Ct) 
values. The  relative  amount  of mRNA  expression was 
calculated by the comparative ∆∆Ct method.
Western blot analysis
The protein extracts for cell lysates were prepared 
in  a  Cell  Lysis  Buffer  (Cell  Signaling,  Danvers, MA) 
containing 1 mM PMSF. Total cell lysates containing 
equivalent amounts of protein were separated on NuPAGE 
4–12%  Bis-Tris  gels  (Invitrogen)  and  transferred  to 
PVDF membranes. The membranes were incubated with 
specific primary antibodies and subsequently horseradish 
peroxidase-conjugated secondary antibody. Following 
incubation with the antibody, proteins were visualized 
using  ECL  detection  system  (Buckinghamshire,  UK). 
The anti-NTSR1 antibody was purchased from Santa 
Cruz Biotechnology  (Santa Cruz,  CA). The  antibodies 
for c-Myc and Cyclin D1 were obtained from Epitomics 
(Burlingame,  CA). The  antibody  for  β-actin  used  as  a 
loading control was from Cell Signaling.
Methylation analysis
Methylation of 5’ regions of NTSR1 and NTSR2 
was  analyzed  using  MSP  (methylation-specific  PCR) 
and  bisulfite  sequencing  analyses.  Briefly,  PCR  was 
performed  using  bisulfite-modified  genomic  DNA  by 
MethylCode  Bisulfite  Conversion Kit  (Invitrogen)  and 
the primers which were designed using Methyl Primer 
Express Software v1.0 (Applied Biosystems) and shown in 
Supplementary Table S1. The PCR products for MSP were 
visualized by 2% agarose gel. For bisulfite-sequencing, 
PCR  products were  cloned  into  the TOPO TA  cloning 
vector (Invitrogen) and the plasmids from individual 
bacterial colonies were sequenced.
Cell proliferation
Equal numbers of BON cells transfected with 
siRNA  or  shRNA  were  plated  in  24-well  plates.  Cell 
proliferation was assessed at 48 h after seeding directly 
by cell counting using a Beckman Coulter Cell Viability 
Analyzer (Beckman-Coulter, Fullerton, CA).
Soft agar assay
To measure anchorage-independent growth, BON 
cells  were  plated  in  growth  medium  containing  0.4% 
agarose in six-well plates onto a bottom layer of solidified 
0.8% agarose. After incubation for 4 weeks, colonies were 




A  Boyden  chamber  migration  assay  with  type  I 
collagen-coated Transwells was carried out with control 








BON cells were plated in 24-well plates and 
transiently  transfected  with  the  IL-8  reporter  (0.4  μg) 
and  the  Renilla  luciferase  reporter  (0.05  μg)  using 
Lipofectamine  2000  according  to  the  manufacturer’s 
instructions  (Invitrogen).  For  SR-48692  treatment, 
Oncotarget26968www.impactjournals.com/oncotarget
0 (DMSO) or 5 μM SR-48692 were treated into BON cells 






plates were coated with type I collagen and washed with 
PBS. Equal numbers of detached BON cell clones were 
plated to each coated well and incubated for 15 min. 
After 37°C incubation, unattached cells were removed by 
washing with PBS, and the adherent cells were fixed, and 
then stained with crystal violet. The plate was washed and 
dried completely. Quantification was performed through 




To compare the migratory activity of stable 
knockdown of NTSR1, a wounding migration assay was 
performed with control and the two BON cell clones 
expressing  NTSR1  shRNA.  The  wounded  monolayers 
using the Culture-Insert (Ibidi, Munich, Germany) were 
incubated  for  22  h. The  cells were  fixed with  ice-cold 
methanol and stained with crystal violet. Quantification 
was carried out by measuring the migrated distance.
Human Alu sequence PCR-based assay
To determine the invasive effect of NTSR1, human 
Alu sequence PCR-based assay was performed as described 
previously [34]. Stable BON cells in PBS were inoculated 
on artificially-generated air sacs at 1 × 107 cells per chick 
chorioallantoic membrane (CAM) of 9 day chick embryos. 
After 3 d, genomic DNA was isolated from lower CAMs 
and  then used  as  a  template of PCR amplification. The 




deviation  (SD)  were  calculated  to  summarize  mRNA 
levels, number of cells, colony formation, migrated and 
attached cell number, luciferase activity and migration 
distance for each experiment. Bar graphs were generated 
to  represent mean  (±  SD)  fold  changes  of  increase  or 
decrease in experimental groups relative to control. 
Within respective experiments, comparisons between two 
groups were performed using two-sample t-tests, whereas 
comparisons across groups were accomplished using 
one-way analysis of variance models and test for linear 
trend of increasing dose levels or pairwise comparisons 
with control group were subsequently performed using 
contrast statements. Normality assumptions of the analysis 
of variance and two-sample t-tests for each outcome were 
assessed. p-values  <  0.05 were  considered  statistically 
significant.
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